Form 4 Filing for Hepion Pharmaceuticals, Inc.

Gary S. Stetz, Interim CEO, Director, and 10% owner of Hepion Pharmaceuticals, Inc. (HEPA), reported a transaction on April 21, 2026. He acquired 1,250,000 shares of common stock at a price of $0.04 per share. This transaction was made through the Stetz Belgiovine CPA 401K F/B/O Gary S. Stetz. Following the transaction, Mr. Stetz directly owns 1,250,000 shares of common stock. The filing is a Form 4, indicating a change in beneficial ownership.